A Phase III randomised, Open-Label, Multi-centre study Assessing the Clinical Benefit of Isatuximab (SAR650984) in Combination with Bortezomib (Velcade), Lenalidomide (Revlimid) and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma not Eligible for Transplant (IMROZ)

Project: Research

Project Description

NMA HREC Reference Number: HREC/17/SVH/289
NMA SSA Reference Number: SSA/18/MonH/49
Monash Health Ref: RES-18-0000-058X
StatusActive
Effective start/end date24/05/19 → 23/05/24
View all
View less

Keywords

  • clinical trial
  • treatment efficacy
  • myeloma
  • clinical trial
  • treatment efficacy
  • myeloma
  • clinical trial
  • treatment efficacy
  • myeloma